

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**





Folic Acid

Ethylenediamine
EEDQ



Folate NH₂



^{99m}Tc-EC-folate




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A

FIG. 6B




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10




FIG. 11A




FIG. 11B




FIG. 12

3-10-1999

EC-(2-NIM)2 after adding serum

Date: Mar 10 1999
Data File:

Start time: 16:02

Accum time: 00:00:50
Plate: 1 Lane: 1

Elect Resolution: NORMAL

(Amp. Range: 0 - 2047)

Stop counts: 50000

Stop Counts Region: 0.00 to 20.00 cm

Rf Calculations: Origin: 1.50 cm

Solvent Front: 19.00 cm

Integration Parameters: Auto Integration

Peak slope: 1.0

Min width: 0.1

Min %: 2.0

Total Count Region: 0.00cm to 20.00cm

Total Counts: 53170

Total CPM: 63810

Reg. #	Start (cm)	Stop (cm)	Center (cm)	Rf	Region Counts	Region CPM	% of Tot Reg	% of Tot Cn
1	0.60	4.40	2.50	0.06	4557	5468	9.02	8.5
2	8.20	16.80	12.56	0.63	45980	55180	90.98	86.4
TOTAL					50540	60650	100.00	95.0





FIG. 13

$^{99m}\text{Tc-EC-NIM}$


$^{99m}\text{Tc-EC}$



4 HOUR

$^{99m}\text{Tc-EC-NIM}$

$^{99m}\text{Tc-EC}$



15 MIN.

FIG. 14A




FIG. 14B




FIG. 15A

*^{99m}Tc-EC-Nitroimidazole (NIM)
(100 μ Ci/mouse, iv.)*

15 MIN.

30 MIN.

1 HOUR

2 HOUR








FIG. 15B


^{99m}Tc-EC-Nitroimidazole (NIM)




15 MIN.



30 MIN.




1 HOUR



2 HOUR


FIG. 15C

*^{99m}Tc-EC-Nitroimidazole (NIM)
(100 μ Ci/mouse, iv.)*




TUMOR

15 MIN.




TUMOR

30 MIN.



TUMOR


1 HOUR




TUMOR

2 HOUR

FIG. 15D




L-GAP



+


(1) Sulfo-NHS, EDAC



EC-GAP


Synthesis of EC-GAP

FIG.
16




30 MIN.

TUMOR




2 HOUR

TUMOR



15 MIN.


TUMOR



1 HOUR


TUMOR

FIG. 17




30 MIN.

TUMOR




2 HOUR

TUMOR



15 MIN.

TUMOR



1 HOUR

TUMOR

FIG. 18





FIG. 19A


^{99m}Tc -EC-Annexin V
(100 μCi /mouse, iv.)

15 MIN.




TUMOR

30 MIN.




TUMOR

1 HOUR



TUMOR

2 HOUR



TUMOR

FIG. 19B




FIG. 20A




FIG. 20B




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28



FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34





FIG. 35




Synthetic scheme of ^{99m}Tc -EC-neomycin.

FIG. 36

$^{99m}\text{Tc-EC}$

$^{99m}\text{Tc-EC-Neomycin}$



Planar image of breast tumor-bearing rats after administration of $^{99m}\text{Tc-EC}$ and $^{99m}\text{Tc-EC-Neomycin}$ (100 $\mu\text{Ci/rat}$, iv.) showed that the tumor could be well visualized from 0.5-4 hours postinjection.

FIG. 37A

Scintigraphic image of breast tumor-bearing rats after administration of $^{99m}\text{Tc-EC}$ and $^{99m}\text{Tc-EC-neomycin}$ (100 $\mu\text{Ci/rat}$, iv.) showed that the tumor could be well visualized from 0.5-4 hours postinjection.

753717-NEO	6012000	WONKWANG
MOGRAPHY EC-NEO		
LT LAT-2H		RT LAT-2H
LT LAT-2H		RT LAT-2H

Scintimammography with ^{99m}Tc -EC- neomycin (30 mCi, iv.) of a breast cancer patient. Images taken two hours post-injection.

EC




FIG. 38A

^1H -NMR of EC.

Neomycin




FIG. 38B

^1H -NMR of neomycin.

EC-Neomycin




FIG. 38C

¹H-NMR of EC-neomycin.

EC-Neo 10mm/50mm 10113




FIG. 39 Mass spectrometry of EC-neomycin (M^+ 1112.55).

UV Wavelength Scan of EC




FIG. 40A

UV wavelength scan of EC.

UV Wavelength Scan of Neomycin




FIG. 40B

UV wavelength scan of neomycin.

UV Wavelength Scan of EC-Neomycin




FIG. 40C

UV wavelength scan of EC-neomycin.

SUMMARY REPORT

EC-NEOMYCIN 30mg + EC

Tc-99m

METHANOL-AMMONIUM ACETATE

Date: Feb 03 2000

Start time: 12:45

Accum time: 00:03:01

Data File:

Plate: 1 Lane: 1

Elect Resolution: NORMAL

(Amp. Range: 0 - 2047)

Rf Calculations: Origin: 0.00 cm

Solvent Front: 20.00 cm

Integration Parameters: Auto Integration

Peak slope: 1.0

Min width: 0.1

Min %: 2.0

Total Count Region: 0.00cm to 20.00cm

Total Counts: 48360

Total CPM: 16030

Reg. #	Start (cm)	Stop (cm)	Center (cm)	Rf	Region Counts	Region CPM	% of Tot Reg	% of Tot Cnt
1	6.50	14.90	10.57	0.53	45000	14920	100.00	93.05
TOTAL					45000	14920	100.00	93.05




FIG. 41

Radio-TLC analysis of ^{99m}Tc-EC-neomycin.

^{99m}Tc-EC-NEO


Column: Bio-Rad Carbohydrate, Aminex HPLX-87C, 250x4mm

Eluent: H₂O

Flow Rate: 0.4ml/min

Detector: Radiochemical

Temp: 85.0°C



RUN 2 JAN 28, 1999 15:48:56
 AREA
 RT. AREA TYPE WIDTH AREA%
 5.023 84274507.7 84.274507.7 100.000000
 TOTAL AREA=84274507.7
 TOTAL COUNTS=1.000000E+00

FIG. 42

HPLC analysis of ^{99m}Tc-EC-neomycin (radioactive detector).

^{99m}Tc-EC-NEO

Column: Bio-Rad Carbohydrate, Aminex HPX-87C, 250x4mm


Eluent: H₂O

Flow Rate: 0.4ml/min

Detector: UV, 254nm

Temp: 85.0°C

RUN # 2 JAN 28. 1999 00:54:29
START



RUN # 2 JAN 28. 1999 00:54:29

RT	AREA	TYPE	WIDTH	AREA%
2.325	353506480	SPH	.498	99.71163
5.185	382604	BV	.265	.15126
5.620	255901	VB	.132	.10712

TOTAL AREA=2.5955E+08


NO. FACTOR=1.0000E+00

* TIME 15:10:00
JUN 28. 1999 15:10:00

* LMT SP .5 12
 * ALL 2" x 10"
 * INPSM / 10"
 * COST: 1.15
 * MAX CAPACITY: 1244

ZEXU = 0. -1.474
 W112 = /
 CHI SP = 0.5
 W112 = 0
 INKSM = /
 W112 = 0.54

* KUN * 1 JAN 28. 1999 15:31:29
STAXI



Column: Bio-Rad Carbohydrate,
Aminex HPLX-87C, 250x4mm

Eluent: H₂O

Flow Rate: 0.4ml/min

Detector: Radiochemical

Temp: 85.0°C

RUND 1 JAN 28, 1999 15131129

AREA	RI	AREA	TYPE	WIDTH	AREA
4.284	108-12040	PV	1.900	100.00000	

TOTAL AREA=1.0371E+08
MUL FACTOR=1.0000E+00

FIG. 44

HPLC analysis of ^18F -FDG (radioactive detector).


¹⁸F-FDG

• DATE 1/28/99
JAN 28. 1999 00:16:15

• CH1 SP .5 0
• ATT 2 0 0
• THRESH 7 0
• LIST: LIST
PEAK CAPACITY: 1244

ZERO = 0. -11.179
ATT 2 = 0
CH1 SP = 0.5
HR REJ = 0
THRESH = 7
PL MD = 0.04

• RUN # 1 JAN 28. 1999 00:37:02
START



Column: Bio-Rad Carbohydrate,
Aminex HPX-87C, 250x4mm
Eluent: H₂O
Flow Rate: 0.4ml/min
Detector: UV, 254nm
Temp: 85.0°C

RUN# 1 JAN 28. 1999 00:37:02

FIG. 45

HPLC analysis of ¹⁸F-FDG (UV 254 nm).

% of Drug Uptake in Lung Cancer Cell Line (A549)




FIG. 46

In vitro cellular uptake assay of a series of ^{99m}Tc -EC-drug conjugates in lung cancer cell line. ^{99m}Tc -EC- neomycin showed

% of Drug Uptake in Human Lung Cancer Cell Line (A549)




FIG. 47
Effect of glucose on cellular (A549) uptake of ^{99m}Tc -EC- neomycin and ^{18}F -FDG.

% of Drug Uptake in Human Lung Cancer Cell Line (H1299)




FIG. 48A

Effect of glucose on cellular (H11299) uptake of ^{99m}Tc -EC-

Effects of Glucose Loading on ^{99m}Tc-EC-Neomycin In Human Lung Cancer Cell Line (H1299)




FIG. 48B





FIG. 49

Synthesis of $^{99\text{m}}\text{Tc-EC-Glucosamine}$

Hexokinase Assay of Glucose

WAVELENGTH SCAN/0

03/01/00 14:41




301.5 nm 0.889 ABS
342.0 nm 2.044 ABS

FIG. 50

Hexokinase Assay of Glucosamine

WAVELENGTH SCAN/0

03/01/00 14:50




301.5 nm 0.193 ABS
341.5 nm 0.360 ABS

FIG. 51

Hexokinase Assay of EC-Glucosamine

WAVELENGTH SCAN/0

03/01/00 14:45



302.5 nm 1.897 ABS
341.5 nm 0.523 ABS

FIG. 52

Hexokinase Assay of EC-GAP-Glucosamine

WAVELENGTH SCAN/0

03/01/00 15:37





FIG. 53



D(+)-Glucosamine

EC-GAP


^{99m}Tc-EC-GAP-Glucosamine

FIG. 54
Synthesis of ^{99m}Tc -EC-GAP-Glucosamine

In Vitro Cellular Uptake of ^{99m}Tc -EC in Human Lung Cancer Cell Line (A549)




FIG. 55A

In Vitro Cellular Uptake of ^{99m}Tc -EC-DG-GAP in Human Lung Cancer Cell Line (A549)




FIG. 55B

In Vitro Cellular Uptake of ^1F FDG in Human Lung Cancer Cell Line (A549)




FIG. 55C

Tumor-to-tissue count density ratios of ^{86}mTc -EC-GAP in breast tumor-bearing rats
(n=3/Interval; 10 $\mu\text{Ci/rat}$, IV)




FIG. 56

**In Vitro Cellular Uptake of ^{18}F FDG with Glucose Loading at 2 Hours Post-Injection in Breast
Cancer Cell Line (13762)**




FIG. 57

% Uptake of ^{99m}Tc-EC-Neomycin in Breast Tumor-Bearing Rats




FIG. 58





FIG. 59 Synthetic scheme of $^{99\text{m}}\text{Tc-EC-deoxyglucose}$.



Glucosamine




FIG. 62

^1H -NMR of glucosamine.

0653528480

04-03 18:55 MON FROM: WON KJANG HOSP


0653528480

1 00117137453372

PAGE: 01

Method: DEFAULT File: BABGCCAF.R01 Raw data User: EC-Glucosami

(99m Tc EC-DG TLC)



Integrals: BABGCCAF.R01

Channel: H-3		Detector:					
Name	Start - End	RT	Height (cps)	Area (Counts)	%Total (%)	%ROI (%)	
Bkg 1	0: 00- 2: 19	1: 09	539. 7				
Rgn 1	2: 19- 3: 02	2: 47	31606. 2	263570. 8	97. 99	100. 00	
Bkg 2	3: 02- 3: 27	3: 14	250. 1				
1 Peak				263570. 8	97. 99	100. 00	
Total Area	=	268986. 1 Counts					
Bkg Area	=	89999. 9 Counts					
Unallocated	=	5415. 3 Counts (2. 01%)					

Trace Parameters: BABGCCAF.R01 H-3

Trace Display Smoothing: 0.0 s
 Trace Display Shift: 0.0 s
 Trace Display Factor: 1.000
 Channel Shift: 0.0 s
 Channel Factor: 1.000

Regions were added manually.


FIG. 63

Radio-TLC analysis of ^{99m}Tc-EC-DG.

^{99m}Tc-EC-deoxyglucose

8 Rad Aminex HPX-87C
column
250 x 4 mm
.4 ml/min. H₂O at
25°C
Radioactive Scan

• ATT 2 7 8
• RUN 0 5 MAR 30. 1999 14143128
START: not ready




RUN 5 MAR 30. 1999 14143128

RT	AREA	TYPE	WIDTH	AREA*
3.328	33350000	SV	.013	100.00000

TOTAL AREA=3.335E+07
MUL FACTOR=1.0000E+00

Radioactive Scan

• RUN 0 6 MAR 30. 1999 15109139
START



RUN 6 MAR 30. 1999 15109139

RT	AREA	TYPE	WIDTH	AREA*
3.701	16671104	SV	.310	100.00000

TOTAL AREA=1.6671E+07

^{99m}Tc-EC

FIG. 64

HPLC analysis of ^{99m}Tc-EC-deoxyglucose and ^{99m}Tc-EC-
(radioactive detector).

• ATT 2^ BREAK


• BREAK

• LIST: ATT 2^ = 7

• ATT 2^ 8 0

• RUN 0 7 MAR 30, 1999 15132137

START



Radioactive Scan

Mixed Tc-99m
EC-Deoxy-Glucose
EC

^{99m}Tc -EC-deoxyglucose + ^{99m}Tc -EC
(mixed)

RUN# 7 MAR 30, 1999 15132137

AREA#	RT	AREA	TYPE	WIDTH	AREA#
	3.355	22173760	BV	.448	50.46186
	3.918	21767872	VV	.387	49.53814

TOTAL AREA=4.3942E+07
MUL FACTOR=1.0000E+00


FIG. 65

HPLC analysis of ^{99m}Tc -EC-deoxyglucose and ^{99m}Tc -EC
(radioactive detector, mixed).

Hexokinase Assay of Glucose

WAVELENGTH SCAN/0

03/01/00 14:41



301.5 nm 0.889 ABS
342.0 nm 2.044 ABS

FIG. 66

Hexokinase assay of glucose.

Hexokinase Assay of FDG

WAVELENGTH SCAN/0

03/09/00 14:34




FIG. 67

Hexokinase assay of FDG.

Hexokinase Assay of EC-Glucosamine (EC-DG)

WAVELENGTH SCAN/0

03/01/00 14:45




FIG. 68

Hexokinase assay of EC-DG.

% of Drug Uptake in Lung Cancer Cell Line (A549)




FIG. 69

In vitro cellular uptake assay of ^{99m}Tc -EC-deoxyglucose, ^{99m}Tc -EC and ^{18}F -FDG in lung cancer cell line (A549). ^{99m}Tc -EC-DG showed similar uptake compared to ^{18}F -FDG.

In Vitro Cellular Uptake of ^{99m}Tc -EC-DG in Breast Cancer Cells after Glucose Loading (2 hours
Incubation; 2uCi/well; 50,000 cells/well; 0.5mL/well)




FIG. 70
Effect of d- and l-glucose on breast cellular (13762 cell line) uptake
of ^{99m}Tc -EC-DG.

In Vitro Cellular Uptake of ^{18}F FDG in Breast Cancer Cells after Glucose Loading (2 hours
incubation; 2uCi/well; 50,000 cells/well; 5mL/well)




FIG. 71 Effect of d- and l-glucose on breast cellular (13762 cell line) uptake of ^{18}F -FDG.

In Vitro Cellular Uptake of ^{18}F FDG in Lung Cancer Cells after Glucose Loading (2 hours incubation;
2uCi/well; 50,000 cells/well; 5mL/well)




FIG. 72

Effect of d- and l-glucose on lungcellular (A549 cell line) uptake of ^{18}F -FDG.

In Vitro Cellular Uptake of ^{99m}Tc -EC-DG in Lung Cancer Cells after Glucose Loading (2 hours incubation; $2\mu\text{Ci}/\text{well}$; 50,000 cells/well; $0.5\text{mL}/\text{well}$)




FIG. 73
Effect of d- and l-glucose on breast cellular (A549 cell line) uptake of ^{99m}Tc -EC-DG.

Effect of Intravenous Injection of Glucosamine and EC-DG on Blood Glucose Level in Rats




FIG. 74
Effect of *in vivo* blood glucose level induced by glucosamine and EC-DG (1.2 mmol/kg, i.v.).

Effect of Intravenous Injection of FDG and FDG+Insulin on Blood Glucose Level in Rats




FIG. 75 Effect of *in vivo* blood glucose level induced by FDG (1.2 and 1.9 mmol/kg, i.v.) and insulin.

Tumor-to-Tissue Count Density Ratios of ^{99m}Tc -EC-Deoxyglucose in Breast Tumor-Bearing Rats




FIG. 76 Tumor-to-tissue count density ratios of ^{99m}Tc -EC-deoxyglucose in breast tumor-bearing rats.

In Vivo Uptake of ^{99m}Tc -EC-Deoxyglucose in Breast Tumor-Bearing Rats




FIG. 77 In vivo biodistribution of ^{99m}Tc -EC-deoxyglucose in breast tumor-bearing rats.

In Vivo Uptake of ^{99m}Tc -EC-Deoxyglucose in Lung Tumor-Bearing Nude Mice




FIG. 78 In vivo tissue uptake of ^{99m}Tc -EC-deoxyglucose in lung tumor-bearing mice.

In Vivo Uptake of ^{99m}Tc -EC-Neomycin in Lung Tumor-Bearing Nude Mice




FIG. 79 In vivo tissue uptake of ^{99m}Tc -EC-neomycin in lung tumor-bearing mice.

In Vivo Uptake of ^{18}F FDG in Lung Tumor-Bearing Nude Mice





FIG. 80 In vivo tissue uptake of ^{18}F -FDG in lung tumor-bearing mice.

$^{99m}\text{Tc-EC}$

$^{99m}\text{Tc-EC-Glucose(6)}$



0.5



2



4hrs



0.5



2



4hrs

Planar image of breast tumor-bearing rats after administration of $^{99m}\text{Tc-EC}$ and $^{99m}\text{Tc-EC-Glucose(6)}$ ($100\mu\text{Ci/rat}$, iv.) showed that the tumor could be well visualized from 0.5-4 hours postinjection.

FIG. 81

Planar image of breast tumor-bearing rats after administration of $^{99m}\text{Tc-EC}$ and $^{99m}\text{Tc-EC-deoxyglucose}$ ($100\mu\text{Ci/rat}$, iv.) showed that the tumor could be well visualized from 0.5-4 hours

Case 1 1/42

Dx : anaplastic astrocytoma



Pre OP



Post OP

NA YOUNG SOON 697800 F42 03A-2000 WONKWANG INTV HOSP


99mTc EC DG 1.5H

INFERIOR->SUPERIOR

EC--DG Scan




POD-25D

99mTc EC DG scan of patient with ectopic pregnancy



Case 11761

Dx: anaplastic astrocytoma with hemorrhage




Pre -OP

Post-OP

FIG. 83A MRI of a patient with hemorrhagic astrocytoma.

SEO 50K RY 79085 F1 05Apr2000 WONKWANG UNIV HOSP



EC-DG Scan POD-26D

FIG. 83B SPECT with ^{99m}Tc -EC-DG of a patient with astrocytoma.

Case 5 : M/62

Dx : Meningioma



FIG. 84A MRI of a patient with benign meningioma.

0-83290 WONKWAN UNITA HOSP

INFERIOR->SUPERIOR:

SPECT with $^{99m}\text{Tc-EC-DG}$ of a patient with benign meningioma

CASE 4. M/F

Dx: Pul. nodule (only necrotic material on biopsy)

TB pleurisy




FIG. 85A CT of a patient with TB in lung.




FIG. 85B

SPECT with ^{99m}Tc -EC-DG of a patient with TB showed no focal

Case 5 : 59/M

Dx: Squamous carcinoma




Pre RTX



Post RTX



Pre RTX



Post RTX

JUNG KI WOON

EC DG 1H

758434 M59

10Apr2000

WONKWANG UNIV HOSP



LUNG CANCER POST RTX 1WK


ANT

POST

1H

FIG. 86B Whole body images of ^{99m}Tc -EC-DG of a patient with lung cancer

JUNG T NOON 7584321459 10APR2000 WONKWANG UNIV HOSP



INFERIOR->SUPERIOR

EC DG 1H 30 MIN LUNG CANCER POST RTX 1WK

SPECT with ^{99m}Tc -EC-DG of a patient with lung cancer, the tumor showed focal intensified uptake.

FIG. 86C